You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 22, 2024

DrugPatentWatch Small Molecules Dashboard

Accurate, objective, and timely intelligence

Other Sections: Biologics Excipients Drug Price Drug Sales Litigation Investigational Drugs AI Research Assistant

Quick Search

Drug Name

Search by drug name:


AI Research Assistant

Ask Anything…

Questions you can ask:

  • How did _________'s marketing evolve with generics?
  • Can you tell me the current total market value of _________ used in clinical settings?
  • How will _________ generics affect market competition?
  • What is the market share forecast for _________?
  • What role did partnerships play in _________'s market dominance?

Advanced Searches

US Popular Searches 

Generic Entry

DrugPatentWatch® Estimated Upcoming Generic Entry Dates
Anticipated Loss-of-Exclusivity (LOE) dates for branded drugs

Unapproved (DESI) Drugs

Upcoming 180-Day Patent Challenge Exclusivity Expirations
Possibility for unrestricted generic entry after patent challenge

Upcoming Litigation Opportunities
NCE Exclusivity Expirations

Tentative Approvals
Identify first generic entrants

Authorized Generic Drugs

US Regulatory and Patent Information 

Single-Source Off-Patent Drugs

Search for Off-Patent Drugs by Number of Sources:

1 Source  2 Sources  3 Sources  4 Sources  1-4 Sources  
Company Name

Search by company name:

New Drug Application (NDA) Number

Search by NDA number:

Drug Patent Expiration

2024   2025   2026   2027   2028   2029   2030   2031   2032   2033   2034   2035   2036   2037   2038   2039   2040   2041   2042   2043  

Search by patent number:

Regulatory Exclusivity

Search for exclusivity expiring in:


Search by exclusivity type:

Search Text in Patent Claims

Search for a keyword (e.g. 'substantially') or a phrase (e.g. 'consisting essentially of') in patent claims:


Approval Date

Search for drugs approved in:


Recent Patent Updates

These are patents which have been reported by the FDA since the last major update; they are not yet in the main database.

Recent Additions

All Recent Patent Additions >>

Recent Delistings

All Recently Delisted Patents >>

Patent Challenge and Generic Entry 

Recent Paragraph IV (Patent) Challenges
Tradename Submission date
RETEVMO May 08, 2024
TABRECTA May 06, 2024
PEMAZYRE April 17, 2024

All Paragraph IV Challenges >>

Tentative Approvals (First Generic Entrants)

The "tentative" approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Search by applicant name:


Search by generic drug name:


All Tentative Approvals >>

Authorized Generic Drugs
Tradename Ingredient Marketing Start
FLECTOR diclofenac epolamine Jun 19, 2024
VIIBRYD vilazodone hydrochloride Jun 05, 2024
KARBINAL ER carbinoxamine maleate Jun 01, 2024

All Authorized Generics >>

International Patent Information 

International Patents

Patents by country:

Supplementary Protection Certificates

Supplementary Protection Certificiates by country:


Drug Class and Dosage 

Medical Subject Heading (MeSH) Category

Search by MeSH Category:


Search by dosage:

Raw API and Finished Product Suppliers 

Bulk API Vendors

Search by branded drug / ingredient name:

Finished Product Suppliers

Search by tradename:


Search by ingredient:


Clinical Trials and Trend Graphs 

Clinical Trials

Search by branded drug / ingredient name:


Upgrade for More Features

Upgrade to a full subscription to unlock our entire dataset and to enjoy subscriber-only features.

Whether you need access for yourself or for your whole team, DrugPatentWatch offers subscription plans tailored to your needs. Attractive pricing is available for small groups or for enterprise-wide access.

For more information see the Plans and Pricing and Discount Schedule. Please contact us with any questions.

➤ See Plans and Pricing
Contact Sales

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.